Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00044915
Status:
COMPLETED
Last Update Posted:
2009-06-12
First Post:
2002-09-06
Brief Title:
Repinotan in Patients With Acute Ischemic Stroke
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy Safety Tolerability and Pharmacokinetic Pharmacodynamic Effects of a Targeted Exposure of Intravenous Repinotan in Patients With Acute Ischemic Stroke
Status:
COMPLETED
Status Verified Date:
2009-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this trial is to evaluate Repinotan HCl in patients with acute ischemic stroke At study entry patients will be randomized to Repinotan HCl or placebo in a 11 ratio The total treatment period wil be 72 hours
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None